Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 1;29(23):4728-4732.
doi: 10.1158/1078-0432.CCR-23-0917.

The New NCI Precision Medicine Trials

Lyndsay N Harris  1 , Charles D Blanke  2 , Harry P Erba  3 , James M Ford  4 , Robert J Gray  5 , Michael L LeBlanc  6 , Siwen Hu-Lieskovan  7 , Mark R Litzow  8 , Selina M Luger  9 , Funda Meric-Bernstam  10 , Peter J O'Dwyer  11 , Megan K D Othus  12 , Katerina Politi  13 , Lois E Shepherd  14 , Carmen J Allegra  1 , Helen X Chen  1 , S Percy Ivy  1 , Larissa A Korde  1 , Richard F Little  1 , Lisa M McShane  1 , Jeffrey A Moscow  1 , David R Patton  15 , Magdalena Thurin  1 , Laura M Yee  1 , James H Doroshow  1
Affiliations

The New NCI Precision Medicine Trials

Lyndsay N Harris et al. Clin Cancer Res. .

Abstract

Basket, umbrella, and platform trial designs (master protocols) have emerged over the last decade to study precision medicine approaches in oncology. First-generation trials like NCI-MATCH (Molecular Analysis for Therapy Choice) have proven the principle that studying targeted therapies on a large scale is feasible both from the laboratory and clinical perspectives. However, single-agent targeted therapies have shown limited ability to control metastatic disease, despite careful matching of drug to target. As such, newer approaches employing combinations of targeted therapy, or targeted therapy with standard therapies, need to be considered. The NCI has recently embarked on three second-generation precision medicine trials to address this need: ComboMATCH, iMATCH, and myeloMATCH. The design of these trials and necessary infrastructure are discussed in the following perspective.

PubMed Disclaimer

Figures

Figure 1. The New Precision Medicine Initiatives of the National Cancer Institute.
Figure 1.
The New Precision Medicine Initiatives of the National Cancer Institute.
Figure 2. NCI resources supporting the Precision Medicine Initiatives.
Figure 2.
NCI resources supporting the Precision Medicine Initiatives.
See this image and copyright information in PMC

References

    1. Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, et al. Delivering precision oncology to patients with cancer. Nat Med 2022;28:658–65. - PubMed
    1. Middleton G, Robbins H, Andre F, Swanton C. A state-of-the-art review of stratified medicine in cancer: towards a future precision medicine strategy in cancer. Ann Oncol 2022;33:143–57. - PubMed
    1. Flaherty KT, Gray R, Chen A, Li S, Patton D, Hamilton SR, et al. The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design. J Natl Cancer Inst 2020;112:1021–9. - PMC - PubMed
    1. Flaherty KT, Gray RJ, Chen AP, Li S, McShane LM, Patton D, et al. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol 2020;38:3883–94. - PMC - PubMed
    1. Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol 2020;21:1353–65. - PubMed